These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 11280890

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 24. alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
    Paick JS, Ku JH, Shin JW, Yang JH, Kim SW.
    BJU Int; 2006 May 27; 97(5):1017-23. PubMed ID: 16643483
    [Abstract] [Full Text] [Related]

  • 25. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N.
    J Urol; 1999 Jun 27; 161(6):2002-8. PubMed ID: 10332490
    [Abstract] [Full Text] [Related]

  • 26. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E, Lee C.
    Br J Urol; 1997 Oct 27; 80(4):606-11. PubMed ID: 9352700
    [Abstract] [Full Text] [Related]

  • 27. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb 27; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 28. [Terazosine in the treatment of benign prostatic hypertrophy].
    Caine M.
    J Urol (Paris); 1993 Feb 27; 99(6):311-3. PubMed ID: 7516376
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, Tokai Urological Clinical Trial Group.
    BJU Int; 2005 Sep 27; 96(4):581-6. PubMed ID: 16104914
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov 27; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 35. [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
    Tamaki M, Ueda T, Kageyama S.
    Hinyokika Kiyo; 1999 Dec 27; 45(12):827-30. PubMed ID: 10659415
    [Abstract] [Full Text] [Related]

  • 36. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH, Hong SJ, Lee MS.
    Int J Urol; 2005 Feb 27; 12(2):159-65. PubMed ID: 15733110
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
    Woods AL.
    Mil Med; 1992 Jul 27; 157(7):361-4. PubMed ID: 1382248
    [Abstract] [Full Text] [Related]

  • 40. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
    Low BY, Liong ML, Yuen KH, Chee C, Leong WS, Chong WL, Khan NA, Cheah PY, Liong KK.
    J Urol; 2008 Apr 27; 179(4):1461-9. PubMed ID: 18295277
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.